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Abstract 
Pancreatic cancer is a malignant neoplasm of the pancreas. It does not cause any 
symptoms in the early stage, and later symptoms are nonspecific, thus the disease is 
usually diagnosed when already advanced. In 2008, pancreatic cancer ranked eighth on 
the list of the 10 most common cancers among men in Croatia and tenth on the list of 
the most common cancers among Croatian women. Pancreatic cancer has a poor 
prognosis, with a survival time of only 6–8 months for metastatic disease. Gemcitabine is 
the standard chemotherapeutic option. Other chemotherapeutic agents include 
5-fluorouracil and leucovorin. In this paper, we present a case of a patient diagnosed 
with locally advanced and metastatic pancreatic cancer, who is still alive and currently 
receives his fourth line of chemotherapy 5 years after the diagnosis. Following disease 
progression on gemcitabine chemotherapy, he was treated with chemoradiotherapy 
which, however, had no effect. We then applied cisplatin monochemotherapy which 
offered excellent disease control, was well tolerated by the patient and, although 
somewhat obsolete in this form, showed to be a valuable chemotherapeutic option. 
 
Introduction 
Pancreatic cancer is a malignant neoplasm of the pancreas. Endocrine pancreatic 
tumors account for only about 1% of all cases. In contrast, exocrine tumors are far more 
common, with 95% of them being adenocarcinomas while the remaining 5% include 
adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid 
carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with 
osteoclast-like giant cells [1]. Because pancreatic cancer does not cause any symptoms in Case Rep Oncol 2011;4:367–370 
DOI: 10.1159/000330775 
Published online: 
August 6, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 





the early stage and the later symptoms are nonspecific and vary, the disease is usually 
diagnosed when already advanced and, thus, the survival is poor. Each year, 
approximately 32,000 patients are diagnosed with pancreatic cancer in the United States, 
and approximately 31,000 patients die from it each year, making pancreatic cancer the 
fourth leading cause of cancer-related death [2]. In 2008, with an incidence rate of 
374/100,000 and a mortality rate of 363/100,000, pancreatic cancer ranked eighth on the 
list of the 10 most common cancers among men in Croatia [3]. The incidence and 
mortality rates of pancreatic cancer among Croatian women were somewhat lower, with 
349 and 316 per 100,000, respectively, making it number 10 on the list of the most 
common cancers [3]. 
According to the analysis of 684 patients treated for pancreatic cancer in the Memorial 
Sloan-Kettering Cancer Center, the median survival time for patients with pancreatic 
ductal carcinoma who underwent resection was 14.3 months, but only 4.9 months for 
unresectable patients [4]. Gemcitabine is the standard chemotherapy option [5]. 
Capecitabine has been shown to provide long-term survival (approx. 4 years) in 2 patients 
with metastatic pancreatic cancer after gemcitabine treatment failure, possibly due to its 
higher activity of thymidine phosphorylase, an enzyme that activates 5-fluorouracil  
(5-FU) in tumor tissues, and thus its higher thymidine phosphorylase/dihydropyrimidine 
dehydrogenase ratio which could predict survival benefit with 5-FU-based agents [6]. 
Case Report 
A 42-year-old male with jaundice, weight loss, nocturnal upper right quadrant abdominal pain, 
diarrhea and postprandial epigastric pain was hospitalized after ultrasonically suspected infiltration in 
the head of the pancreas. An abdominal CT scan showed an expansive lesion retropancreatically, 
between the pancreas and inferior vena cava and below the portal vein, measuring 41 × 25 mm, with 
enlarged para-aortic and interaorticocaval lymph nodes, a dilated intra- and extrahepatic biliary tree 
and stenosis of the common bile duct. An endoscopic retrograde cholangiopancreatography was 
performed, and the patient was referred to an abdominal surgeon. During explorative laparotomy, the 
tumor was found to be inoperable because of local vascular infiltration and liver metastases. 
Pathohistological diagnosis confirmed the clinical diagnosis. 
One month later, chemotherapy with gemcitabine was started. After 6 cycles of chemotherapy (i.e. 
22 applications), a CT scan showed no liver metastases; however, the tumor in the head of the pancreas 
was still visible and unchanged in size. The patient was again referred to a surgeon who declined the 
possibility of an operative procedure. Therefore, chemoradiotherapy was started during which the 
patient received the planned dose of 41.4 Gy (23 × 1.8 Gy) simultaneously with monthly intravenous 
5-FU (5-day chemotherapy, 6 cycles). CT monitoring of the tumor response to chemoradiotherapy 
showed a relapse of the liver metastases, with no change in the size of the primary tumor or enlarged 
abdominal lymph nodes. Thus, a third line of chemotherapy with cisplatin monotherapy was started. 
After 5 cycles, a CT scan revealed stationary liver lesions and an unchanged primary tumor. The disease 
remained stable for 18 months until the patient had to be hospitalized for high blood glucose levels. 
Along with the diagnosis of insulin-dependent diabetes mellitus, new liver metastases were found. Five 
years after the diagnosis, the patient is still alive and receives the fourth line of chemotherapy (5-FU and 
leucovorin). 
Discussion 
The prognosis for patients with metastatic pancreatic cancer is extremely poor, with a 
median survival time of 3–6 months [2]. The standard cytotoxic treatment is gemcitabine 
[5]. However, the addition of other agents such as cisplatin, irinotecan, oxaliplatin, Case Rep Oncol 2011;4:367–370 
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taxanes and biologically targeted agents has shown higher response rates [7]. According 
to a recently published meta-analysis, gemcitabine in combination with capecitabine or 
oxaliplatin is associated with improved overall survival and overall response rates in 
locally advanced and metastatic pancreatic cancer patients, while the gemcitabine/ 
cisplatin combination showed no survival benefit compared to the gemcitabine 
monotherapy [8]. 
For refractory pancreatic cancer, however, there is no consensus regarding the optimal 
treatment. Oettle et al. [9], when they evaluated FOLFOX as a second-line treatment in 
advanced pancreatic cancer, found that chemotherapy offers better overall survival to 
refractory patients as compared to best supportive care. According to the final results of 
the CONKO-003 trial, the addition of oxaliplatin to 5-FU and leucovorin improves 
overall survival and progression-free survival when compared to treatment with 5-FU and 
leucovorin alone [10]. Some studies have demonstrated the efficacy of gemcitabine/ 
oxaliplatin combination chemotherapy as second-line treatment [11]. Combination of 
oxaliplatin and capecitabine after treatment failure with gemcitabine has shown some 
activity [6]. Paclitaxel as monotherapy has considerable efficacy and low toxicity in 
second-line treatment [12], as does FOLFIRI [13]. Bevacizumab and erlotinib 
combination showed poor results [14], as did the use of sunitinib as a single agent [15]. 
Overall, little progress has been made so far in the field of refractory pancreatic cancer 
treatment, and there is no evidence-based treatment recommended for these patients. 
Cisplatin monotherapy is seldom considered in modern treatment of refractory 
pancreatic cancer, although it is a widely used chemotherapeutic drug and the first 
member of a class of platinum-containing anticancer drugs. The number of patients 
initially responding to this therapy is high; however, the majority of cancer patients 
eventually relapse with cisplatin-resistant disease. According to our possibilities and 
clinical experience, we introduced cisplatin administered by bi-weekly infusion as 
third-line chemotherapy in our patient. This resulted in a remarkable response, providing 
18 months of disease stability and contributing to a 5-year survival in an initially 
unresectable patient with liver and lymph node metastases. Thus, although today 
surpassed by new exciting drugs and their combinations, cisplatin monotherapy should 
be considered in refractory pancreatic cancer patients with satisfactory serum creatinine 
levels. It represents a valuable option in these patients, especially when one is faced with 
non-medical limitations in form of means restriction. Case Rep Oncol 2011;4:367–370 
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